Association of Contraception with Medical Conditions

Association of Contraception with Medical Conditions

FSRH CEU Statement to published systematic review: The relationship between progestin hormonal contraception and depression: a systematic review - March 2018

08 March 2018

Much recent media attention has been given to the subject of a potential association between hormonal contraception and depression. The FSRH CEU monitors and reports relevant emerging evidence. A new systematic review published in Contraception examines the existing evidence relating to risk of depression associated with use of progestogen-only contraception (POC).1 The authors of the review conclude that the bulk of the evidence does not support an association between use of POC and depression based on validated measures. Meta-analysis was not possible due to the heterogeneity of studies.

This document is up-to-date

CEU Statement: Oral Contraceptive Use and Cancer Risk (September 2007)

01 September 2007

This study supports the use of the oral contraceptive pill as a safe and effective method of contraception. The study confirms findings from other studies about the protective effects of oral contraceptive use in reducing the risk of certain types of cancer.

This document is up-to-date

CEU Statement: Glioma and Hormonal Contraception (February 2015)

01 February 2015

Gliomas are glial cell tumours which can occur in the spinal cord or the brain and are the most common type of brain tumour. They vary greatly in their likely rate of growth, differentiation and prognosis. Glioblastoma multiforme is the most common and most aggressive primary brain tumour.

This document is up-to-date

CEU Statement: Depot Medroxyprogesterone Acetate (DMPA, Depo- Provera) and Risk of HIV Acquisition (January 2015)

01 January 2015

Progestogen-only injectable contraception is widely used across the world and is particularly popular in resource poor countries with a high incidence of HIV infection e.g. in sub-Saharan Africa. It is clearly important therefore to establish whether there is any relationship between the use of injectable contraception and increased risk of HIV acquisition.

This document is up-to-date

CEU Statement: Oral Contraceptives and Multiple Sclerosis (March 2014)

01 March 2014

Various news stories have reported the findings detailed in the AAN press release which stated that compared to women who did not use hormonal contraceptives, women who did, were 35 percent more likely to develop Multiple Sclerosis and that the findings suggested that hormonal contraception may be contributing to the rise in the rate of MS among women.

This document is up-to-date

FSRH CEU Statement: Response to Study Contemporary Hormonal Contraception and the Risk of Breast Cancer (December 2017)

12 December 2017

FSRH's Clinical Effectiveness Unit (CEU) reviews an observational study published in the New England Journal of Medicine. The study reports that, in the Danish study population, women who were currently using any method of hormonal contraception* (HC) or had done so within the last 6 months were 20% more likely to be diagnosed with breast cancer than those who had never used HC.

This document is up-to-date

FSRH CEU Statement: Response to Study Intrauterine Contraception Use and Cervical Cancer Risk - January 2018

18 January 2018

This statement responds to a recent study that reported that women who had used intrauterine contraception (IUC) were over one third less likely to experience invasive cervical cancer than women who had not used IUC. The study has received media attention and the FSRH CEU considered it important to put the findings into perspective. January 2018

This document is up-to-date